I nɔmal fɔ mek ɛnibɔdi fil big big fred ɛn shɔk we i yɛri di wɔd dɛn "colorectal cancer". Bɔt bikɔs di tin dɛn we dɔn apin na mɛrɛsin tide, bɔku nyu tritmɛnt dɛn de we go ɛp wi fɔ bia wit dɛn kayn sik dɛn de. Tide, wi go tɔk bɔt wan "targeted therapy" we difrɛn frɔm tradishɔnal kemotɛrapi ɛn we de tɔk mɔ bɔt kansa sɛl dɛn.
Fɔ tɔk am simpul wan, wetin na dɛn Monoclonal Antibodies ya?
Bifo wi ɔndastand dis, lɛ wi tek wan luk pan di wɔndaful difens sistɛm we wi bɔdi gɛt. We wan jem, lɛk baktri ɔ vayrɔs, kam insay wi bɔdi, wi imyun sistɛm kin mek spɛshal prɔtin dɛn we kin no dɛn tin ya we kin kam insay wi, atak dɛn, ɛn pwɛl dɛn. wi kin kכl dεn ya "bodiguards," כ antibodi dεm fכ bi mכr prεsis.
naw, dεn ``(Monoclonal Antibodies)`` dεm na wan kayn atifishal antibodi dεm we dεn mek na lab we dεn de yuz spεshal tεknכlכji. Dɛn mek dɛn tin ya fɔ atak wan patikyula target nɔmɔ. Fɔ tɔk di kɔrɛkt tin, dɛn mek dɛn fɔ no wan patikyula tin, lɛk wan patikyula prɔtin we de ɔp wan kansa sɛl, fɔ atak am nɔmɔ, ɛn pwɛl da kansa sɛl de .
Dis tan lɛk kɔmando we dɛn tren spɛshal wan we kin fɛn ɛnimi na ples we bɔku pipul dɛn kin de ɛn atak da ɛnimi de nɔmɔ ɛn nɔ du ɛni ɔda pɔsin bad. So, insted fכ damej gud sεl dεm na di bכdi lεk rεgulεr kεmothεrapi, dεn kin εkspεkt se dis tritmεnt mכt fכ gεt sכm sayd ifekt biכs i de mכr spεsifi k.
Drug dɛm wae de stɔp di blɔd vesel dɛm fɔ gro pan kansa (Angiogenesis Inhibitors) .
Kansa nɔto sɔntin we jɔs de gro. I tan lɛk plant. I nid tin fɔ it fɔ mek i liv, fɔ gro, ɛn fɔ gro. Fɔ gɛt dis it, di kansa sɛl dɛn kin gro nyu blɔd vesel dɛn rawnd dɛnsɛf. wi kכl dis prכsεs ``angiogenesis.`` So, if wi stכp di bכdi vεsul dεm we de saplae dεn "fud εn drink" ya to di kεnsar, wi kin stכp di kεnsar fכ gro, nכto? Na dat wi de kɔl di klas fɔ drɔgs we de du dat.
Dis na aw Bevacizumab (Avastin) de wok:
Bevacizumab (brand nem: Avastin) na wan impɔtant mɛrɛsin na dis klas. di kεnsar sεl dεm de sεnd wan signal we de tεl dεm fכ "bil bכdi vεsεl dεm." dis signal dεn kכl am vaskulεr εndoteyl growth fכktכ, כ VEGF. Wetin Avastin de du na fɔ blok da signal de fɔ mek i nɔ rich di sayt we dɛn want fɔ rich. fכ simpul tεm dεm, i de intasept di "lεta fכ bil bכdi vεsul dεm" we di kεnsar de sεnd εn pwεl am.
Dis kin mek di kansa nɔ de mek nyu blɔd vesel dɛn, ɛn dis kin mek di kansa nɔ gro kwik kwik wan. Dɛn dɔn gri fɔ dis mɛrɛsin fɔ kɔlon kansa we dɔn skata (mɛtastas) to ɔda pat dɛn na di bɔdi. Pan ɔl we i nɔ kin ebul fɔ mɛn di kansa ɔltogɛda, stɔdi dɛn dɔn sho se we dɛn gi Avastin wit kemotɛrapi, i kin mek di sikman dɛn liv lɔng lɛk 5 mɔnt .
`Fruquintinib (Fruzaqla)`, `ramucirumab (Cyramza)`, ɛn `ziv-aflibercept (Zaltrap)` na sɔm pan di nyu drɔgs dɛm we de tɔch `VEGF` bak.
Aw dɛn kin gi Avastin? Wetin na di bad tin dɛn we kin apin to pɔsin?
Avastin na injɛkshɔn we dɛn kin put insay di bɛlɛ (IV). Dɛn kin gi am ɛvri tu to tri wik wit kemotɛrapi.
I rili impɔtant fɔ no bɔt di sayd ɛfɛkt dɛn we dis mɛrɛsin kin gɛt.
| Tayp fɔ di sayd ɛfɛkt | Tɔk bɔt |
|---|---|
| Kɔmɔn sayd ɛfɛkt dɛn |
|
| Siriɔs sayd ɛfɛkt dɛn |
|
Drug dεm we de afekt di growth fכ di kansa sεl dεm dairekt wan
Sɛtuximab (Erbitux) ɛn panitumumab (Vectibix) na tu ɔda kayn monoklɔnal antibodi dɛm. Dɛn tin ya kin wok difrɛn we. dεn de tכk to wan protin we dεn kכl epidamal growth fכktכ rεsεptכr (EGFR) we de na di sεf fכ di kεnsar sεl dεm.
Tink bɔt dis `EGFR` lɛk `On` switch we de tɛl wan kansa sɛl fɔ `divayd kwik ɛn gro mɔ.` Wetin di drɔgs `Erbitux` ɛn `Vectibix` de du na fɔ sidɔm pan dis switch ɛn `blɔk` am. Dɔn, di natura signal we de tɛl di sɛl fɔ gro nɔ kin ebul fɔ opin di switch. Dis we ya, dɛn kin kɔntrol di we aw di kansa sɛl dɛn de gro.
Udat dɛn gi dis mɛrɛsin?
Dɛn dɔn gri fɔ trit Erbitux ɛn Vectibix ɔl tu fɔ trit kɔlon kansa we dɔn skata to ɔda pat dɛn na di bɔdi.
Dɛn kin gi di Erbitux vaysin wan tɛm insay di wik, dɛn kin gi am in wan ɔ wit di kemotɛrapi drɔg we dɛn kɔl irinotecan (Camptosar). Dɛn kin gi di Vectibix vaysin ɛvri tu wik wit ɔda kemotɛrapi drɔgs.
I rili impɔtant fɔ mek bifo yu gi dis mɛrɛsin, dɛn fɔ du spɛshal jenɛtik muteshɔn tɛst pan yu kansa sɛl dɛn fɔ si if dis mɛrɛsin go wok fɔ da kansa de. Dɛn tin ya nɔ fayn fɔ ɔl di kansa dɛn. So, dɛn kin rili du dis tɛst.
Wetin na di sayd ɛfɛkt dɛm fɔ Erbitux ɛn Vectibix?
Dɛn mɛrɛsin ya gɛt sɔm patikyula sayd ɛfɛkt dɛn bak.
| Kɔmɔn sayd ɛfɛkt dɛn we Erbitux ɛn Vectibix kin gɛt | |
|---|---|
| Prɔblɛm dɛn we de na di skin | Blista dɛn we tan lɛk akni, skin rash, ɛn dray skin. Bɔt di strenj tin na dat, sɔntɛnde dɛn tin ya we kin apin na di skin kin min se di mɛrɛsin de wok fayn fayn wan agens kansa. |
| Ɔda sayd ɛfɛkt dɛn |
|
Mɛsej we dɛn kin kɛr go na os
- Monoclonal Antibodies na wan advans tritmεnt we de spεshal tכk εn atak di kεnsar sεl dεm. Dɛn difrɛn frɔm di tritmɛnt dɛn we dɛn kin gi ɔltɛm wit kemotɛrapi.
- Sɔm drɔgs kin kɔt di blɔd we de gi di kansa, ɛn ɔda wan dɛn kin blok di signal sistɛm we de mek di kansa sɛl dɛn gro.
- Ɔl dɛn mɛrɛsin ya gɛt dɛn yon sayd ɛfɛkt. Tɔk bɔt dɛn tin ya opin wan wit yu dɔktɔ bifo yu bigin fɔ trit yu.
- Dɛn tritmɛnt ya nɔr fayn fɔ ɔlman. Yu dɔktɔ go disayd us tritmɛnt go fayn fɔ yu bay di kayn kansa we yu gɛt, aw fa i dɔn skata, ɛn di rizɔlt fɔ spɛshal jenɛtik tɛst.
- If yu ɔ pɔsin na yu famili gɛt kansa, nɔ panik. Tɔk to yu dɔktɔ we de mɛn kansa bɔt ɔl di tritmɛnt dɛn we de, di gud ɛn bad tin dɛn we dɛn kin du, ɛn tek di maynd fɔ fes di tritmɛnt.
💬 Comments (0)
No kɔmɛnt nɔ de yet. Ad yu kɔmɛnt ya fɔ di fɔs tɛm.
Ad yu kɔmɛnt